J&J reported $25.4B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Abbott USD 13.01B 423M Sep/2026
Amgen USD 10.4B 300M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Baxter International USD 2.98B 20M Sep/2026
Bayer EUR 10.05B 820M Sep/2026
Becton, Dickinson and Co. USD 5.3B 300M Sep/2026
Biogen USD 2.8B 60M Sep/2026
Boston Scientific USD 5.14B 300M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
CONMED USD 335.6M 7.9M Sep/2026
Cooper Companies USD 1.07B 15.3M Jun/2026
Dexcom USD 1.34B 30M Sep/2026
Edwards Lifesciences USD 1.72B 20M Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Globus Medical USD 763.72M 25.89M Sep/2026
Insulet USD 842M 40.3M Sep/2026
Integra LifeSciences USD 411.18M 7.62M Sep/2026
Intuitive Surgical USD 3.05B 158.7M Sep/2026
J&J USD 25.4B 89M Sep/2026
Medtronic USD 9.8B 0 Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Merit Medical Systems USD 416.24M 2.56M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 14.44B 2.49B Sep/2026
Stryker USD 6.5B 100M Sep/2026
Tandem Diabetes Care USD 283.69M 29.09M Sep/2026
Teva Pharmaceutical Industries USD 4.37B 8.3B Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026
Zimmer Biomet Holdings USD 2.06B 120M Sep/2026
Zoetis USD 2.4B 100M Sep/2026